Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
SPRYCEL
(dasatinib) Tablets
SPRYCEL (dasatinib) is a kinase inhibitor. The chemical name for dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate. The molecular formula is C22H26ClN7O2S • H2O, which corresponds to a formula weight of 506.02 (monohydrate). The anhydrous free base has a molecular weight of 488.01. Dasatinib has the following chemical structure:
 |
Dasatinib is a white to off-white powder. The drug substance is insoluble in water and slightly soluble in ethanol and methanol.
SPRYCEL tablets are white to off-white, biconvex, film-coated tablets containing dasatinib, with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium dioxide, and polyethylene glycol.
SPRYCEL (dasatinib) is indicated for the treatment of adult patients with
SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients with
The recommended starting dosage of SPRYCEL for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily. Tablets should not be crushed, cut, or chewed; they should be swallowed whole. SPRYCEL can be taken with or without a meal, either in the morning or in the evening.
The recommended starting dosage for pediatrics is based on body weight as shown in Table 1. The recommended dose should be administered orally once daily with or without food. Recalculate the dose every 3 months based on changes in body weight, or more often if necessary.
Do not crush, cut or chew tablets. Swallow tablets whole. The exposure in patients receiving a crushed tablet is lower than in those swallowing an intact tablet.
Table 1: Dosage of SPRYCEL for Pediatric Patients
| Body Weight (kg)a | Daily Dose (mg) |
| 10 to less than 20 | 40 mg |
| 20 to less than 30 | 60 mg |
| 30 to less than 45 | 70 mg |
| at least 45 | 100 mg |
| aTablet dosing is not recommended for patients weighing less than 10 kg. | |
Avoid the use of concomitant strong CYP3A4 inducers and St. John’s wort. If patients must be coadministered a strong CYP3A4 inducer, consider a SPRYCEL dose increase. If the dose of SPRYCEL is increased, monitor the patient carefully for toxicity [see DRUG INTERACTIONS].
Avoid the use of concomitant strong CYP3A4 inhibitors and grapefruit juice. Recommend selecting an alternate concomitant medication with no or minimal enzyme inhibition potential, if possible. If SPRYCEL must be administered with a strong CYP3A4 inhibitor, consider a dose decrease to:
For patients taking SPRYCEL 60 mg or 40 mg daily, stop SPRYCEL until the inhibitor is discontinued. Allow a washout period of approximately 1 week after the inhibitor is stopped before reinitiating SPRYCEL.
These reduced doses of SPRYCEL are predicted to adjust the area under the curve (AUC) to the range observed without CYP3A4 inhibitors; however, clinical data is not available with these dose adjustments in patients receiving strong CYP3A4 inhibitors. If SPRYCEL is not tolerated after dose reduction, either discontinue the strong CYP3A4 inhibitor or stop SPRYCEL until the inhibitor is discontinued. Allow a washout period of approximately 1 week after the inhibitor is stopped before the SPRYCEL dose is increased [see DRUG INTERACTIONS].
In clinical studies of adult CML and Ph+ ALL patients, dose escalation to 140 mg once daily (chronic phase CML) or 180 mg once daily (advanced phase CML and Ph+ ALL) was allowed in patients who did not achieve a hematologic or cytogenetic response at the recommended starting dosage.
Escalate the SPRYCEL dose as shown in Table 2 in pediatric patients who do not achieve a hematologic or cytogenetic response at the recommended starting dosage.
Table 2: Dose Escalation for Pediatric CML
| Formulation | Dose (maximum dose per day) | |
| Starting Dose | Escalation | |
| Tablets | 40 mg | 50 mg |
| 60 mg | 70 mg | |
| 70 mg | 90 mg | |
| 100 mg | 120 mg | |
In clinical studies, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy. Hematopoietic growth factor has been used in patients with resistant myelosuppression. Guidelines for dose modifications for adult and pediatric patients are summarized in Tables 3 and 4, respectively.
Table 3: Dose Adjustments for Neutropenia and
Thrombocytopenia in Adults
| Chronic Phase CML (starting dose 100 mg once daily) | ANC* <0.5 x 109/L or Platelets <50 x 109/L |
|
| Accelerated Phase CML, Blast Phase CML and Ph+ ALL (starting dose 140 mg once daily) | ANC* <0.5 x 109/L or Platelets <10 x 109/L |
|
| *ANC: absolute neutrophil count | ||
Table 4: Dose Adjustments for Neutropenia and
Thrombocytopenia in Pediatric Patients
| Dose (maximum dose per day) | |||
| Original Starting Dose | One-Level Dose Reduction | Two-Level Dose Reduction | |
| 1. If cytopenia persists for more than 3 weeks, check if cytopenia is related to leukemia (marrow aspirate or biopsy). | 40 mg | 20 mg | ** |
| 60 mg | 40 mg | 20 mg | |
| 2. If cytopenia is unrelated to leukemia, stop SPRYCEL until ANC* ≥1.0 x 109/L and platelets ≥75 x 109/L and resume at the original starting dose or at a reduced dose. | 70 mg | 60 mg | 50 mg |
| 100 mg | 80 mg | 70 mg | |
| 3. If cytopenia recurs, repeat marrow aspirate/biopsy and resume SPRYCEL at a reduced dose. | |||
| *ANC: absolute neutrophil count ** lower tablet dose not available |
|||
For all pediatric patients, if Grade ≥ 3 neutropenia or thrombocytopenia recurs during complete hematologic response (CHR), interrupt SPRYCEL and resume at a reduced dose. Implement temporary dose reductions for intermediate degrees of cytopenia and disease response as needed.
If a severe non-hematologic adverse reaction develops with SPRYCEL use, treatment must be withheld until the event has resolved or improved. Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the severity and recurrence of the event [see WARNINGS AND PRECAUTIONS].
In clinical studies, treatment with SPRYCEL in adults and pediatric patients was continued until disease progression or until no longer tolerated by the patient. The effect of stopping treatment on long-term disease outcome after the achievement of a cytogenetic response (including complete cytogenetic response [CCyR]) or major molecular response (MMR and MR4.5) has not been established.
SPRYCEL is an antineoplastic product. Follow applicable special handling and disposal procedures.1
SPRYCEL (dasatinib) Tablets are available as 20-mg, 50-mg, 70-mg, 80-mg, 100-mg, and 140-mg white to off-white, biconvex, film-coated tablets [see HOW SUPPLIED].
SPRYCEL® (dasatinib) tablets are available as described in Table 18.
Table 18: SPRYCEL Trade Presentations
| NDC Number | Strength | Description | Tablets per Bottle |
| 0003-0527-11 | 20 mg | white to off-white, biconvex, round, film-coated tablet with “BMS” debossed on one side and “527” on the other side | 60 |
| 0003-0528-11 | 50 mg | white to off-white, biconvex, oval, film-coated tablet with “BMS” debossed on one side and “528” on the other side | 60 |
| 0003-0524-11 | 70 mg | white to off-white, biconvex, round, film-coated tablet with “BMS” debossed on one side and “524” on the other side | 60 |
| 0003-0855-22 | 80 mg | white to off-white, biconvex, triangle, film-coated tablet with “BMS” and “80” (BMS over 80) debossed on one side and “855” on the other side | 30 |
| 0003-0852-22 | 100 mg | white to off-white, biconvex, oval, film-coated tablet with “BMS 100” debossed on one side and “852” on the other side | 30 |
| 0003-0857-22 | 140 mg | white to off-white, biconvex, round, film-coated tablet with “BMS” and “140” (BMS over 140) debossed on one side and “857” on the other side | 30 |
SPRYCEL tablets should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
SPRYCEL is an antineoplastic product. Follow special handling and disposal procedures.1
Personnel who are pregnant should avoid exposure to crushed or broken tablets.
SPRYCEL tablets consist of a core tablet, surrounded by a film coating to prevent exposure of healthcare professionals to the active substance. The use of latex or nitrile gloves for appropriate disposal when handling tablets that are inadvertently crushed or broken is recommended, to minimize the risk of dermal exposure.
REFERENCES
1. http://www.osha.gov/SLTC/hazardousdrugs/index.html
Distributed by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA. Â Revised: Nov 2018
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to SPRYCEL at all doses tested in clinical studies (n=2809), including 324 adult patients with newly diagnosed chronic phase CML, 2388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase CML or Ph+ ALL, and 97 pediatric patients with chronic phase CML. The median duration of therapy in a total of 2712 adult patients was 19.2 months (range 0 to 93.2 months). In a randomized trial in patients with newly diagnosed chronic phase CML, the median duration of therapy was approximately 60 months. The median duration of therapy in 1618 adult patients with chronic phase CML was 29 months (range 0 to 92.9 months).
The median duration of therapy in 1094 adult patients with advanced phase CML or Ph+ ALL was 6.2 months (range 0 to 93.2 months).
In two non-randomized trials in 97 pediatric patients with chronic phase CML (51 patients newly diagnosed and 46 patients resistant or intolerant to previous treatment with imatinib), the median duration of therapy was 51.1 months (range 1.9 to 99.6 months).
In the overall population of 2712 adult patients, 88% of patients experienced adverse reactions at some time and 19% experienced adverse reactions leading to treatment discontinuation.
In the randomized trial in adult patients with newly diagnosed chronic phase CML, drug was discontinued for adverse reactions in 16% of patients with a minimum of 60 months of follow-up. After a minimum of 60 months of follow-up, the cumulative discontinuation rate was 39%. Among the 1618 patients with chronic phase CML, drug-related adverse reactions leading to discontinuation were reported in 329 (20.3%) patients; among the 1094 patients with advanced phase CML or Ph+ ALL, drug-related adverse reactions leading to discontinuation were reported in 191 (17.5%) patients.
Among the 97 pediatric subjects, drug-related adverse reactions leading to discontinuation were reported in 1 patient (1%).
Adverse reactions reported in ≥10% of adult patients, and other adverse reactions of interest, in a randomized trial in patients with newly diagnosed chronic phase CML at a median follow-up of approximately 60 months are presented in Table 5.
Adverse reactions reported in ≥10% of adult patients treated at the recommended dose of 100 mg once daily (n=165), and other adverse reactions of interest, in a randomized dose-optimization trial of patients with chronic phase CML resistant or intolerant to prior imatinib therapy at a median follow-up of approximately 84 months are presented in Table 7.
Adverse reactions reported in ≥10% of pediatric patients at a median follow-up of approximately 51.1 months are presented in Table 10.
Drug-related serious adverse reactions (SARs) were reported for 16.7% of adult patients in the randomized trial of patients with newly diagnosed chronic phase CML. Serious adverse reactions reported in ≥5% of patients included pleural effusion (5%).
Drug-related SARs were reported for 26.1% of patients treated at the recommended dose of 100 mg once daily in the randomized dose-optimization trial of adult patients with chronic phase CML resistant or intolerant to prior imatinib therapy. Serious adverse reactions reported in ≥5% of patients included pleural effusion (10%).
Drug-related SARs were reported for 14.4% of pediatric patients.
Adverse reactions (excluding laboratory abnormalities) that were reported in at least 10% of adult patients are shown in Table 5 for newly diagnosed patients with chronic phase CML and Tables 7 and 10 for CML patients with resistance or intolerance to prior imatinib therapy.
Table 5: Adverse Reactions Reported in ≥10% of
Adult Patients with Newly Diagnosed Chronic Phase CML (minimum of 60 months
follow-up)
| Adverse Reaction | All Grades | Grade 3/4 | ||
| SPRYCEL (n=258) |
Imatinib (n=258) |
SPRYCEL (n=258) |
Imatinib (n=258) |
|
| Percent (%) of Patients | ||||
| Fluid retention | 38 | 45 | 5 | 1 |
| Pleural effusion | 28 | 1 | 3 | 0 |
| Superficial localized edema | 14 | 38 | 0 | <1 |
| Pulmonary hypertension | 5 | <1 | 1 | 0 |
| Generalized edema | 4 | 7 | 0 | 0 |
| Pericardial effusion | 4 | 1 | 1 | 0 |
| Congestive heart failure/ cardiac dysfunctiona | 2 | 1 | <1 | <1 |
| Pulmonary edema | 1 | 0 | 0 | 0 |
| Diarrhea | 22 | 23 | 1 | 1 |
| Musculoskeletal pain | 14 | 17 | 0 | <1 |
| Rashb | 14 | 18 | 0 | 2 |
| Headache | 14 | 11 | 0 | 0 |
| Abdominal pain | 11 | 8 | 0 | 1 |
| Fatigue | 11 | 12 | <1 | 0 |
| Nausea | 10 | 25 | 0 | 0 |
| Myalgia | 7 | 12 | 0 | 0 |
| Arthralgia | 7 | 10 | 0 | <1 |
| Hemorrhagec | 8 | 8 | 1 | 1 |
| Gastrointestinal bleeding | 2 | 2 | 1 | 0 |
| Other bleedingd | 6 | 6 | 0 | <1 |
| CNS bleeding | <1 | <1 | 0 | <1 |
| Vomiting | 5 | 12 | 0 | 0 |
| Muscle spasms | 5 | 21 | 0 | <1 |
| a Includes cardiac failure acute, cardiac
failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction
decreased, and left ventricular dysfunction. b Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular. c Adverse reaction of special interest with <10% frequency. d Includes conjunctival hemorrhage, ear hemorrhage, ecchymosis, epistaxis, eye hemorrhage, gingival bleeding, hematoma, hematuria, hemoptysis, intra-abdominal hematoma, petechiae, scleral hemorrhage, uterine hemorrhage, and vaginal hemorrhage. |
||||
A comparison of cumulative rates of adverse reactions reported in ≥10% of patients with minimum follow-up of 1 and 5 years in a randomized trial of newly diagnosed patients with chronic phase CML treated with SPRYCEL are shown in Table 6.
Table 6: Adverse Reactions Reported in ≥10% of
Adult Patients with Newly Diagnosed Chronic Phase CML in the SPRYCEL-Treated
Arm (n=258)
| Adverse Reaction | Minimum of 1 Year Follow-up | Minimum of 5 Years Follow-up | ||
| All Grades | Grade 3/4 | All Grades | Grade 3/4 | |
| Percent (%) of Patients | ||||
| Fluid retention | 19 | 1 | 38 | 5 |
| Pleural effusion | 10 | 0 | 28 | 3 |
| Superficial localized edema | 9 | 0 | 14 | 0 |
| Pulmonary hypertension | 1 | 0 | 5 | 1 |
| Generalized edema | 2 | 0 | 4 | 0 |
| Pericardial effusion | 1 | <1 | 4 | 1 |
| Congestive heart failure/cardiac dysfunctiona | 2 | <1 | 2 | <1 |
| Pulmonary edema | <1 | 0 | 1 | 0 |
| Diarrhea | 17 | <1 | 22 | 1 |
| Musculoskeletal pain | 11 | 0 | 14 | 0 |
| Rashb | 11 | 0 | 14 | 0 |
| Headache | 12 | 0 | 14 | 0 |
| Abdominal pain | 7 | 0 | 11 | 0 |
| Fatigue | 8 | <1 | 11 | <1 |
| Nausea | 8 | 0 | 10 | 0 |
| a Includes cardiac failure acute, cardiac
failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction
decreased, and left ventricular dysfunction. b Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular. |
||||
At 60 months, there were 26 deaths in dasatinib-treated patients (10.1%) and 26 deaths in imatinib-treated patients (10.1%); 1 death in each group was assessed by the investigator as related to study therapy.
Table 7: Adverse Reactions Reported in ≥10% of
Adult Patients with Chronic Phase CML Resistant or Intolerant to Prior Imatinib
Therapy (minimum of 84 months follow-up)
| Adverse Reaction | 100 mg Once Daily Chronic (n=165) |
|
| All Grades | Grade 3/4 | |
| Percent (%) of Patients | ||
| Fluid retention | 48 | 7 |
| Superficial localized edema | 22 | 0 |
| Pleural effusion | 28 | 5 |
| Generalized edema | 4 | 0 |
| Pericardial effusion | 3 | 1 |
| Pulmonary hypertension | 2 | 1 |
| Headache | 33 | 1 |
| Diarrhea | 28 | 2 |
| Fatigue | 26 | 4 |
| Dyspnea | 24 | 2 |
| Musculoskeletal pain | 22 | 2 |
| Nausea | 18 | 1 |
| Skin rasha | 18 | 2 |
| Myalgia | 13 | 0 |
| Arthralgia | 13 | 1 |
| Infection (including bacterial, viral, | 13 | 1 |
| fungal, and non-specified) | ||
| Abdominal pain | 12 | 1 |
| Hemorrhage | 12 | 1 |
| Gastrointestinal bleeding | 2 | 1 |
| Pruritus | 12 | 1 |
| Pain | 11 | 1 |
| Constipation | 10 | 1 |
| a Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalized erythema, genital rash, heat rash, milia, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin irritation, urticaria vesiculosa, and rash vesicular. | ||
Cumulative rates of selected adverse reactions that were reported over time in patients treated with the 100 mg once daily recommended starting dose in a randomized dose-optimization trial of imatinib-resistant or -intolerant patients with chronic phase CML are shown in Table 8.
Table 8: Selected Adverse Reactions Reported in Adult
Dose Optimization Trial (Imatinib-Intolerant or -Resistant Chronic Phase CML)a
| Adverse Reaction | Minimum of 2 Years Follow-up | Minimum of 5 Years Follow-up | Minimum of 7 Years Follow-up | |||
| All Grades Grade 3/4 | All Grades Grade 3/4 | All Grades | Grade 3/4 | |||
| Percent (%) of Patients | ||||||
| Diarrhea | 27 | 2 | 28 | 2 | 28 | 2 |
| Fluid retention | 34 | 4 | 42 | 6 | 48 | 7 |
| Superficial edema | 18 | 0 | 21 | 0 | 22 | 0 |
| Pleural effusion | 18 | 2 | 24 | 4 | 28 | 5 |
| Generalized edema | 3 | 0 | 4 | 0 | 4 | 0 |
| Pericardial effusion | 2 | 1 | 2 | 1 | 3 | 1 |
| Pulmonary hypertension | 0 | 0 | 0 | 0 | 2 | 1 |
| Hemorrhage | 11 | 1 | 11 | 1 | 12 | 1 |
| Gastrointestinal bleeding | 2 | 1 | 2 | 1 | 2 | 1 |
| a Randomized dose-optimization trial results reported in the recommended starting dose of 100 mg once daily (n=165) population. | ||||||
Table 9: Adverse Reactions Reported in ≥10% of
Adult Patients with Advanced Phase CML Resistant or Intolerant to Prior
Imatinib Therapy
| Adverse Reaction | 140 mg Once Daily | |||||
| Accelerated (n=157) |
Myeloid Blast (n=74) |
Lymphoid Blast (n=33) |
||||
| All Grades | Grade 3/4 | All Grades | Grade 3/4 | All Grades | Grade 3/4 | |
| Percent (%)of Patients | ||||||
| Fluid retention | 35 | 8 | 34 | 7 | 21 | 6 |
| Superficial localized edema | 18 | 1 | 14 | 0 | 3 | 0 |
| Pleural effusion | 21 | 7 | 20 | 7 | 21 | 6 |
| Generalized edema | 1 | 0 | 3 | 0 | 0 | 0 |
| Pericardial effusion | 3 | 1 | 0 | 0 | 0 | 0 |
| Congestive heart failure/cardiac dysfunctiona | 0 | 0 | 4 | 0 | 0 | 0 |
| Pulmonary edema | 1 | 0 | 4 | 3 | 0 | 0 |
| Headache | 27 | 1 | 18 | 1 | 15 | 3 |
| Diarrhea | 31 | 3 | 20 | 5 | 18 | 0 |
| Fatigue | 19 | 2 | 20 | 1 | 9 | 3 |
| Dyspnea | 20 | 3 | 15 | 3 | 3 | 3 |
| Musculoskeletal pain | 11 | 0 | 8 | 1 | 0 | 0 |
| Nausea | 19 | 1 | 23 | 1 | 21 | 3 |
| Skin rashb | 15 | 0 | 16 | 1 | 21 | 0 |
| Arthralgia | 10 | 0 | 5 | 1 | 0 | 0 |
| Infection (including bacterial, viral, fungal, and non-specified) | 10 | 6 | 14 | 7 | 9 | 0 |
| Hemorrhage | 26 | 8 | 19 | 9 | 24 | 9 |
| Gastrointestinal bleeding | 8 | 6 | 9 | 7 | 9 | 3 |
| CNS bleeding | 1 | 1 | 0 | 0 | 3 | 3 |
| Vomiting | 11 | 1 | 12 | 0 | 15 | 0 |
| Pyrexia | 11 | 2 | 18 | 3 | 6 | 0 |
| Febrile neutropenia | 4 | 4 | 12 | 12 | 12 | 12 |
| a Includes ventricular dysfunction, cardiac
failure, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy,
diastolic dysfunction, ejection fraction decreased, and ventricular failure. b Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalized erythema, genital rash, heat rash, milia, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin irritation, urticaria vesiculosa, and rash vesicular. |
||||||
Table 10: Adverse Reactions Reported in ≥10% of
Dasatinib-Treated Pediatric Patients (n=97)
| Adverse Reaction | All Grades | Grade 3/4 |
| Percent (%) of Patients | ||
| Headache | 28 | 3 |
| Nausea | 20 | 0 |
| Diarrhea | 21 | 0 |
| Skin rash | 19 | 0 |
| Vomiting | 13 | 0 |
| Pain in extremity | 19 | 1 |
| Abdominal pain | 16 | 0 |
| Fatigue | 10 | 0 |
| Arthralgia | 10 | 1 |
Myelosuppression was commonly reported in all patient populations. The frequency of Grade 3 or 4 neutropenia, thrombocytopenia, and anemia was higher in patients with advanced phase CML than in chronic phase CML (Tables 11 and 12). Myelosuppression was reported in patients with normal baseline laboratory values as well as in patients with pre-existing laboratory abnormalities.
In patients who experienced severe myelosuppression, recovery generally occurred following dose interruption or reduction; permanent discontinuation of treatment occurred in 2% of adult patients with newly diagnosed chronic phase CML and 5% of adult patients with resistance or intolerance to prior imatinib therapy [see WARNINGS AND PRECAUTIONS].
Grade 3 or 4 elevations of transaminases or bilirubin and Grade 3 or 4 hypocalcemia, hypokalemia, and hypophosphatemia were reported in patients with all phases of CML but were reported with an increased frequency in patients with myeloid or lymphoid blast phase CML. Elevations in transaminases or bilirubin were usually managed with dose reduction or interruption. Patients developing Grade 3 or 4 hypocalcemia during SPRYCEL therapy often had recovery with oral calcium supplementation.
Laboratory abnormalities reported in adult patients with newly diagnosed chronic phase CML are shown in Table 11. There were no discontinuations of SPRYCEL therapy in this patient population due to biochemical laboratory parameters.
Table 11: CTC Grade ¾ Laboratory Abnormalities in
Adult Patients with Newly Diagnosed Chronic Phase CML (minimum of 60 months
follow-up)
| SPRYCEL (n=258) |
Imatinib (n=258) |
|
| Percent (%) of Patients | ||
| Hematology Parameters | ||
| Neutropenia | 29 | 24 |
| Thrombocytopenia | 22 | 14 |
| Anemia | 13 | 9 |
| Biochemistry Parameters | ||
| Hypophosphatemia | 7 | 31 |
| Hypokalemia | 0 | 3 |
| Hypocalcemia | 4 | 3 |
| Elevated SGPT (ALT) | <1 | 2 |
| Elevated SGOT (AST) | <1 | 1 |
| Elevated Bilirubin | 1 | 0 |
| Elevated Creatinine | 1 | 1 |
| CTC grades: neutropenia (Grade 3 ≥0.5 - <1.0 x 109/L, Grade 4 <0.5 x 109/L); thrombocytopenia (Grade 3 ≥25 - <50 x 109/L, Grade 4 <25 x 109/L); anemia (hemoglobin Grade 3 ≥65 - <80 g/L, Grade 4 <65 g/L); elevated creatinine (Grade 3 >3 - 6 x upper limit of normal range (ULN), Grade 4 >6 x ULN); elevated bilirubin (Grade 3 >3 - 10 x ULN, Grade 4 >10 x ULN); elevated SGOT or SGPT (Grade 3 >5 - 20 x ULN, Grade 4 >20 x ULN); hypocalcemia (Grade 3 <7.0 - 6.0 mg/dL, Grade 4 <6.0 mg/dL); hypophosphatemia (Grade 3 <2.0 - 1.0 mg/dL, Grade 4 <1.0 mg/dL); hypokalemia (Grade 3 <3.0 - 2.5 mmol/L, Grade 4 <2.5 mmol/L). | ||
Laboratory abnormalities reported in patients with CML resistant or intolerant to imatinib who received the recommended starting doses of SPRYCEL are shown by disease phase in Table 12.
Table 12: CTC Grade 3/4 Laboratory Abnormalities in
Clinical Studies of CML in Adults: Resistance or Intolerance to Prior Imatinib
Therapy
| Chronic Phase CML 100 mg Once Daily (n=165) |
Advanced Phase CML 140 mg Once Daily | |||
| Accelerated Phase (n=157) |
Myeloid Blast Phase (n=74) |
Lymphoid Blast Phase (n=33) |
||
| Percent (%) of Patients | ||||
| Hematology Parameters* | ||||
| Neutropenia | 36 | 58 | 77 | 79 |
| Thrombocytopenia | 24 | 63 | 78 | 85 |
| Anemia | 13 | 47 | 74 | 52 |
| Biochemistry Parameters | ||||
| Hypophosphatemia | 10 | 13 | 12 | 18 |
| Hypokalemia | 2 | 7 | 11 | 15 |
| Hypocalcemia | <1 | 4 | 9 | 12 |
| Elevated SGPT (ALT) | 0 | 2 | 5 | 3 |
| Elevated SGOT (AST) | <1 | 0 | 4 | 3 |
| Elevated Bilirubin | <1 | 1 | 3 | 6 |
| Elevated Creatinine | 0 | 2 | 8 | 0 |
| CTC grades: neutropenia (Grade 3 ≥0.5 - <1.0 x 109/L,
Grade 4 <0.5 x 109/L); thrombocytopenia (Grade 3 ≥25 - <50 x 109/L,
Grade 4 <25 x 109/L); anemia (hemoglobin Grade 3 ≥65 - <80 g/L, Grade
4 <65 g/L); elevated creatinine (Grade 3 >3 - 6 x upper limit of normal
range (ULN), Grade 4 >6 x ULN); elevated bilirubin (Grade 3 >3 - 10 x ULN,
Grade 4 >10 x ULN); elevated SGOT or SGPT (Grade 3 >5 - 20 x ULN, Grade 4
>20 x ULN); hypocalcemia (Grade 3 <7.0 - 6.0 mg/dL, Grade 4 <6.0 mg/dL);
hypophosphatemia (Grade 3 <2.0 - 1.0 mg/dL, Grade 4 <1.0 mg/dL);
hypokalemia (Grade 3 <3.0 - 2.5 mmol/L, Grade 4 <2.5 mmol/L). * Hematology parameters for 100 mg once-daily dosing in chronic phase CML reflects 60-month minimum follow-up. |
||||
Among adult patients with chronic phase CML with resistance or intolerance to prior imatinib therapy, cumulative Grade 3 or 4 cytopenias were similar at 2 and 5 years including: neutropenia (36% vs 36%), thrombocytopenia (23% vs 24%), and anemia (13% vs 13%).
In the pediatric studies, the rates of laboratory abnormalities were consistent with the known profile for laboratory parameters in adults.
A total of 135 patients with Ph+ ALL were treated with SPRYCEL in clinical studies. The median duration of treatment was 3 months (range 0.03 - 31 months). The safety profile of patients with Ph+ ALL was similar to those with lymphoid blast phase CML. The most frequently reported adverse reactions included fluid retention events, such as pleural effusion (24%) and superficial edema (19%), and gastrointestinal disorders, such as diarrhea (31%), nausea (24%), and vomiting (16%). Hemorrhage (19%), pyrexia (17%), rash (16%), and dyspnea (16%) were also frequently reported. Serious adverse reactions reported in ≥5% of patients included pleural effusion (11%), gastrointestinal bleeding (7%), febrile neutropenia (6%), and infection (5%).
The following additional adverse reactions were reported in adult and pediatric patients (n=2809) in SPRYCEL CML and Ph+ ALL clinical studies at a frequency of ≥10%, 1% - <10%, 0.1% - <1%, or <0.1%. These adverse reactions are included based on clinical relevance.
Gastrointestinal Disorders: 1% - <10% - mucosal inflammation (including mucositis/stomatitis), dyspepsia, abdominal distension, constipation, gastritis, colitis (including neutropenic colitis), oral soft tissue disorder; 0.1% - <1% - ascites, dysphagia, anal fissure, upper gastrointestinal ulcer, esophagitis, pancreatitis, gastroesophageal reflux disease; <0.1% - protein losing gastroenteropathy, ileus, acute pancreatitis, anal fistula.
General Disorders and Administration-Site Conditions: ≥10% - peripheral edema, face edema; 1% - <10% - asthenia, chest pain, chills; 0.1% - <1% - malaise, other superficial edema, peripheral swelling; <0.1% - gait disturbance.
Skin and Subcutaneous Tissue Disorders: 1% - <10% - alopecia, acne, dry skin, hyperhidrosis, urticaria, dermatitis (including eczema); 0.1% - <1% - pigmentation disorder, skin ulcer, bullous conditions, photosensitivity, nail disorder, neutrophilic dermatosis, panniculitis, palmar-plantar erythrodysesthesia syndrome, hair disorder; <0.1% - leukocytoclastic vasculitis, skin fibrosis.
Respiratory, Thoracic, and Mediastinal Disorders: 1% - <10% - lung infiltration, pneumonitis, cough; 0.1% - <1% - asthma, bronchospasm, dysphonia, pulmonary arterial hypertension; <0.1% - acute respiratory distress syndrome, pulmonary embolism.
Nervous System Disorders: 1% - <10% - neuropathy (including peripheral neuropathy), dizziness, dysgeusia, somnolence; 0.1% - <1% - amnesia, tremor, syncope, balance disorder; <0.1% - convulsion, cerebrovascular accident, transient ischemic attack, optic neuritis, VIIth nerve paralysis, dementia, ataxia.
Blood and Lymphatic System Disorders: 0.1% - <1% - lymphadenopathy, lymphopenia; <0.1% - aplasia pure red cell.
Musculoskeletal and Connective Tissue Disorders: 1% - <10% - muscular weakness, musculoskeletal stiffness; 0.1% - <1% - rhabdomyolysis, tendonitis, muscle inflammation, osteonecrosis, arthritis; <0.1% - epiphyses delayed fusion (reported at 1% - <10% in the pediatric studies), growth retardation (reported at 1% - <10% in the pediatric studies).
Investigations: 1% - <10% - weight increased, weight decreased; 0.1% - <1% - blood creatine phosphokinase increased, gamma-glutamyltransferase increased.
Infections and Infestations: 1% - <10% - pneumonia (including bacterial, viral, and fungal), upper respiratory tract infection/inflammation, herpes virus infection, enterocolitis infection, sepsis (including fatal outcomes [0.2%]).
Metabolism and Nutrition Disorders: 1% - <10% - appetite disturbances, hyperuricemia; 0.1% - <1% - hypoalbuminemia, tumor lysis syndrome, dehydration, hypercholesterolemia; <0.1% - diabetes mellitus.
Cardiac Disorders: 1% - <10% - arrhythmia (including tachycardia), palpitations; 0.1% - <1% - angina pectoris, cardiomegaly, pericarditis, ventricular arrhythmia (including ventricular tachycardia), electrocardiogram T-wave abnormal, troponin increased; <0.1% - cor pulmonale, myocarditis, acute coronary syndrome, cardiac arrest, electrocardiogram PR prolongation, coronary artery disease, pleuropericarditis.
Eye Disorders: 1% - <10% - visual disorder (including visual disturbance, vision blurred, and visual acuity reduced), dry eye; 0.1% - <1% - conjunctivitis, visual impairment, lacrimation increased, <0.1% - photophobia.
Vascular Disorders: 1% - <10% - flushing, hypertension; 0.1% - <1% - hypotension, thrombophlebitis, thrombosis; <0.1% - livedo reticularis, deep vein thrombosis, embolism.
Psychiatric Disorders: 1% - <10% - insomnia, depression; 0.1% - <1% - anxiety, affect lability, confusional state, libido decreased.
Pregnancy, Puerperium, and Perinatal Conditions: <0.1% - abortion.
Reproductive System and Breast Disorders: 0.1% - <1% - gynecomastia, menstrual disorder.
Injury, Poisoning, and Procedural Complications: 1% - <10% - contusion.
Ear and Labyrinth Disorders: 1% - <10% - tinnitus; 0.1% - <1% - vertigo, hearing loss.
Hepatobiliary Disorders: 0.1% - <1% - cholestasis, cholecystitis, hepatitis.
Renal and Urinary Disorders: 0.1% - <1% - urinary frequency, renal failure, proteinuria; <0.1% - renal impairment.
Immune System Disorders: 0.1% - <1% - hypersensitivity (including erythema nodosum).
Endocrine Disorders: 0.1% - <1% - hypothyroidism; <0.1% - hyperthyroidism, thyroiditis.
The following additional adverse reactions have been identified during post approval use of SPRYCEL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Infections: hepatitis B virus reactivation
Cardiac disorders: atrial fibrillation/atrial flutter
Respiratory, thoracic, and mediastinal disorders: interstitial lung disease
Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome
Renal and urinary disorders: nephrotic syndrome
Blood and lymphatic system disorders: thrombotic microangiopathy
The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see CLINICAL PHARMACOLOGY]. Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a SPRYCEL dose reduction [see DOSAGE AND ADMINISTRATION].
The coadministration of SPRYCEL with strong CYP3A inducers may decrease dasatinib concentrations [see CLINICAL PHARMACOLOGY]. Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a SPRYCEL dose increase.
The coadministration of SPRYCEL with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy.
Do not administer H2 antagonists or proton pump inhibitors with SPRYCEL. Consider the use of antacids in place of H2 antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. Avoid simultaneous administration of SPRYCEL with antacids.
Included as part of the PRECAUTIONS section.
Treatment with SPRYCEL is associated with severe (NCI CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia, which occur earlier and more frequently in patients with advanced phase CML or Ph+ ALL than in patients with chronic phase CML.
In patients with chronic phase CML, perform complete blood counts (CBCs) every 2 weeks for 12 weeks, then every 3 months thereafter, or as clinically indicated. In patients with advanced phase CML or Ph+ ALL, perform CBCs weekly for the first 2 months and then monthly thereafter, or as clinically indicated.
Myelosuppression is generally reversible and usually managed by withholding SPRYCEL temporarily and/or dose reduction [see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS].
SPRYCEL can cause serious and fatal bleeding. In all CML or Ph+ ALL clinical studies, Grade ≥3 central nervous system (CNS) hemorrhages, including fatalities, occurred in <1% of patients receiving SPRYCEL. The incidence of Grade 3/4 hemorrhage, occurred in 5.8% of adult patients and generally required treatment interruptions and transfusions. The incidence of Grade 5 hemorrhage occurred in 0.4% of adult patients. The most frequent site of hemorrhage was gastrointestinal. Most bleeding events in clinical studies were associated with severe thrombocytopenia. In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro.
Concomitant medications that inhibit platelet function or anticoagulants may increase the risk of hemorrhage.
SPRYCEL may cause fluid retention. After 5 years of follow-up in the adult randomized newly diagnosed chronic phase CML study (n=258), Grade 3 or 4 fluid retention was reported in 5% of patients, including 3% of patients with Grade 3 or 4 pleural effusion. In adult patients with newly diagnosed or imatinib-resistant or -intolerant chronic phase CML, Grade 3 or 4 fluid retention occurred in 6% of patients treated with SPRYCEL at the recommended dose (n=548). In adult patients with advanced phase CML or Ph+ ALL treated with SPRYCEL at the recommended dose (n=304), Grade 3 or 4 fluid retention was reported in 8% of patients, including Grade 3 or 4 pleural effusion reported in 7% of patients. In pediatric patients with chronic phase CML, cases of Grade 1 or 2 fluid retention were reported in 10.3% of patients.
Evaluate patients who develop symptoms of pleural effusion or other fluid retention, such as new or worsened dyspnea on exertion or at rest, pleuritic chest pain, or dry cough, promptly with a chest x-ray or additional diagnostic imaging as appropriate. Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. Severe pleural effusion may require thoracentesis and oxygen therapy. Consider dose reduction or treatment interruption [see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS].
SPRYCEL can cause cardiac dysfunction. After 5 years of follow-up in the randomized newly diagnosed chronic phase CML trial in adults (n=258), the following cardiac adverse reactions occurred: cardiac ischemic events (3.9% dasatinib vs 1.6% imatinib), cardiac-related fluid retention (8.5% dasatinib vs 3.9% imatinib), and conduction system abnormalities, most commonly arrhythmia and palpitations (7.0% dasatinib vs 5.0% imatinib). Two cases (0.8%) of peripheral arterial occlusive disease occurred with imatinib and 2 (0.8%) transient ischemic attacks occurred with dasatinib. Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.
SPRYCEL may increase the risk of developing pulmonary arterial hypertension (PAH) in adult and pediatric patients which may occur any time after initiation, including after more than 1 year of treatment. Manifestations include dyspnea, fatigue, hypoxia, and fluid retention. PAH may be reversible on discontinuation of SPRYCEL. Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating SPRYCEL and during treatment. If PAH is confirmed, SPRYCEL should be permanently discontinued.
SPRYCEL may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy. Correct hypokalemia or hypomagnesemia prior to and during SPRYCEL administration.
Cases of severe mucocutaneous dermatologic reactions, including Stevens-Johnson syndrome and erythema multiforme, have been reported in patients treated with SPRYCEL. Discontinue permanently in patients who experience a severe mucocutaneous reaction during treatment if no other etiology can be identified.
Tumor lysis syndrome has been reported in patients with resistance to prior imatinib therapy, primarily in advanced phase disease. Due to potential for tumor lysis syndrome, maintain adequate hydration, correct uric acid levels prior to initiating therapy with SPRYCEL, and monitor electrolyte levels. Patients with advanced stage disease and/or high tumor burden may be at increased risk and should be monitored more frequently [see ADVERSE REACTIONS].
Based on limited human data, SPRYCEL can cause fetal harm when administered to a pregnant woman. Adverse pharmacologic effects of SPRYCEL including hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to SPRYCEL. Advise females of reproductive potential to avoid pregnancy, which may include the use of effective contraception, during treatment with SPRYCEL and for 30 days after the final dose [see Use In Specific Populations].
In pediatric trials of SPRYCEL in chronic phase CML after at least 2 years of treatment, adverse reactions associated with bone growth and development were reported in 5 (5.2%) patients, one of which was severe in intensity (Growth Retardation Grade 3). These 5 cases included cases of epiphyses delayed fusion, osteopenia, growth retardation, and gynecomastia [see ADVERSE REACTIONS and Use In Specific Populations]. Of these 5 cases, 1 case of osteopenia and 1 case of gynecomastia resolved during treatment.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Patients should be informed of the possibility of serious bleeding and to report immediately any signs or symptoms suggestive of hemorrhage (unusual bleeding or easy bruising) [see WARNINGS AND PRECAUTIONS].
Patients should be informed of the possibility of developing low blood cell counts; they should be instructed to report immediately should fever develop, particularly in association with any suggestion of infection [see WARNINGS AND PRECAUTIONS].
Patients should be informed of the possibility of developing fluid retention (swelling, weight gain, dry cough, chest pain on respiration, or shortness of breath) and advised to seek medical attention promptly if those symptoms arise [see WARNINGS AND PRECAUTIONS].
Patients should be informed of the possibility of developing pulmonary arterial hypertension (dyspnea, fatigue, hypoxia, and fluid retention) and advised to seek medical attention promptly if those symptoms arise [see WARNINGS AND PRECAUTIONS].
Patients should be informed to immediately report and seek medical attention for any symptoms such as nausea, vomiting, weakness, edema, shortness of breath, muscle cramps, and seizures, which may indicate tumor lysis syndrome [see WARNINGS AND PRECAUTIONS].
Pediatric patients and their caregivers should be informed of the possibility of developing bone growth abnormalities, bone pain, or gynecomastia and advised to seek medical attention promptly if those symptoms arise [see WARNINGS AND PRECAUTIONS].
Patients should be informed that they may experience nausea, vomiting, or diarrhea with SPRYCEL. If these symptoms are bothersome or persistent, they should seek medical attention.
Advise patients using antacids to avoid taking SPRYCEL and antacids less than 2 hours apart [see DRUG INTERACTIONS].
Patients should be informed that they may experience headache or musculoskeletal pain with SPRYCEL. If these symptoms are bothersome or persistent, they should seek medical attention.
Patients should be informed that they may experience fatigue with SPRYCEL. If this symptom is bothersome or persistent, they should seek medical attention.
Patients should be informed that they may experience skin rash with SPRYCEL. If this symptom is bothersome or persistent, they should seek medical attention.
Patients should be informed that SPRYCEL contains 135 mg of lactose monohydrate in a 100-mg daily dose and 189 mg of lactose monohydrate in a 140-mg daily dose.
If the patient misses a dose of SPRYCEL, the patient should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.
In a 2-year carcinogenicity study, rats were administered oral doses of dasatinib at 0.3, 1, and 3 mg/kg/day. The highest dose resulted in a plasma drug exposure (AUC) level approximately 60% of the human exposure at 100 mg once daily. Dasatinib induced a statistically significant increase in the combined incidence of squamous cell carcinomas and papillomas in the uterus and cervix of high-dose females and prostate adenoma in low-dose males.
Dasatinib was clastogenic when tested in vitro in Chinese hamster ovary cells, with and without metabolic activation. Dasatinib was not mutagenic when tested in an in vitro bacterial cell assay (Ames test) and was not genotoxic in an in vivo rat micronucleus study.
Dasatinib did not affect mating or fertility in male and female rats at plasma drug exposure (AUC) similar to the human exposure at 100 mg daily. In repeat dose studies, administration of dasatinib resulted in reduced size and secretion of seminal vesicles, and immature prostate, seminal vesicle, and testis. The administration of dasatinib resulted in uterine inflammation and mineralization in monkeys, and cystic ovaries and ovarian hypertrophy in rodents.
Based on limited human data, SPRYCEL can cause fetal harm when administered to a pregnant woman. Adverse pharmacologic effects including hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to SPRYCEL. Animal reproduction studies in rats have demonstrated extensive mortality during organogenesis, the fetal period, and in neonates. Skeletal malformations were observed in a limited number of surviving rat and rabbit conceptuses. These findings occurred at dasatinib plasma concentrations below those in humans receiving therapeutic doses of dasatinib [see Data]. Advise a pregnant woman of the potential risk to a fetus.
The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.
Fetal/Neonatal Adverse Reactions
Transplacental transfer of dasatinib has been reported. Dasatinib has been measured in fetal plasma and amniotic fluid at concentrations comparable to those in maternal plasma. Hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to dasatinib. These adverse pharmacologic effects on the fetus are similar to adverse reactions observed in adult patients and may result in fetal harm or neonatal death [see WARNINGS AND PRECAUTIONS].
Human Data
Based on human experience, dasatinib is suspected to cause congenital malformations, including neural tube defects, and harmful pharmacological effects on the fetus when administered during pregnancy.
Animal Data
In nonclinical studies at plasma concentrations below those observed in humans receiving therapeutic doses of dasatinib, embryo-fetal toxicities were observed in rats and rabbits. Fetal death was observed in rats. In both rats and rabbits, the lowest doses of dasatinib tested (rat: 2.5 mg/kg/day [15 mg/m²/day] and rabbit: 0.5 mg/kg/day [6 mg/m²/day]) resulted in embryo-fetal toxicities. These doses produced maternal AUCs of 105 ng•h/mL and 44 ng•h/mL (0.1-fold the human AUC) in rats and rabbits, respectively. Embryo-fetal toxicities included skeletal malformations at multiple sites (scapula, humerus, femur, radius, ribs, and clavicle), reduced ossification (sternum; thoracic, lumbar, and sacral vertebrae; forepaw phalanges; pelvis; and hyoid body), edema, and microhepatia. In a pre- and postnatal development study in rats, administration of dasatinib from gestation day (GD) 16 through lactation day (LD) 20, GD 21 through LD 20, or LD 4 through LD 20 resulted in extensive pup mortality at maternal exposures that were below the exposures in patients treated with dasatinib at the recommended labeling dose.
No data are available regarding the presence of dasatinib in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. However, dasatinib is present in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing children from SPRYCEL, breastfeeding is not recommended during treatment with SPRYCEL and for 2 weeks after the final dose.
Females
SPRYCEL can cause fetal harm when administered to a pregnant woman [see Use In Specific Populations]. Advise females of reproductive potential to avoid pregnancy, which may include the use of effective contraceptive methods, during treatment with SPRYCEL and for 30 days after the final dose.
Infertility
Based on animal data, dasatinib may result in damage to female and male reproductive tissues [see Nonclinical Toxicology].
The safety and efficacy of SPRYCEL in 97 pediatric patients with chronic phase CML were evaluated in two pediatric studies (a Phase I, open-label, non-randomized dose-ranging trial and a Phase II, open-label, non-randomized trial). Fifty-one patients (exclusively from the Phase II trial) were newly diagnosed with chronic phase CML and 46 patients (17 from the Phase I trial and 29 from the Phase II trial) were resistant or intolerant to previous treatment with imatinib. The majority of patients were treated with SPRYCEL tablets 60 mg/m² once daily (maximum dose of 100 mg once daily for patients with high BSA). Patients were treated until disease progression or unacceptable toxicity. The safety profile of dasatinib in pediatric subjects was comparable to that reported in studies in adult subjects with chronic phase CML. Monitor bone growth and development in pediatric patients [see WARNINGS AND PRECAUTIONS].
No differences in confirmed Complete Cytogenetic Response (cCCyR) and MMR were observed between older and younger patients. Of the 2712 patients in clinical studies of SPRYCEL, 617 (23%) were 65 years of age and older, and 123 (5%) were 75 years of age and older. While the safety profile of SPRYCEL in the geriatric population was similar to that in the younger population, patients aged 65 years and older are more likely to experience the commonly reported adverse reactions of fatigue, pleural effusion, diarrhea, dyspnea, cough, lower gastrointestinal hemorrhage, and appetite disturbance, and more likely to experience the less frequently reported adverse reactions of abdominal distention, dizziness, pericardial effusion, congestive heart failure, hypertension, pulmonary edema, and weight decrease, and should be monitored closely.
Experience with overdose of SPRYCEL in clinical studies is limited to isolated cases. The highest overdosage of 280 mg per day for 1 week was reported in two patients and both developed severe myelosuppression and bleeding. Since SPRYCEL is associated with severe myelosuppression [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS], monitor patients who ingest more than the recommended dosage closely for myelosuppression and give appropriate supportive treatment.
Acute overdose in animals was associated with cardiotoxicity. Evidence of cardiotoxicity included ventricular necrosis and valvular/ventricular/atrial hemorrhage at single doses ≥100 mg/kg (600 mg/m²) in rodents. There was a tendency for increased systolic and diastolic blood pressure in monkeys at single doses ≥10 mg/kg (120 mg/m²).
None.
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.
In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
Of 2440 patients treated with SPRYCEL at all doses tested in clinical trials, 16 patients (<1%) had QTc prolongation reported as an adverse reaction. Twenty-two patients (1%) experienced a QTcF > 500 ms. In 865 patients with leukemia treated with SPRYCEL 70 mg BID in five Phase 2 studies, the maximum mean changes in QTcF (90% upper bound CI) from baseline ranged from 7 ms to 13.4 ms.
An analysis of the data from five Phase 2 studies in patients (70 mg BID) and a Phase 1 study in healthy subjects (100 mg single dose) suggests that there is a maximum increase of 3 to 6 milliseconds in Fridericia corrected QTc interval from baseline for subjects receiving therapeutic doses of dasatinib, with associated upper 95% confidence intervals <10 msec.
The pharmacokinetics of dasatinib exhibits dose proportional increases in AUC and linear elimination characteristics over the dose range of 15 mg/day (0.15 times the lowest approved recommended dose) to 240 mg/day (1.7 times the highest approved recommended dose).
At 100 mg QD, the maximum concentration at steady state (Cmax) is 82.2 ng/mL (CV% 69%), area under the plasma drug concentration time curve (AUC) is 397 ng/mL*hr (CV% 55%). The clearance of dasatinib is found to be time-invariant.
The maximum plasma concentrations (Cmax) of dasatinib are observed between 0.5 hours and 6 hours (Tmax) following oral administration.
Food Effect
A high-fat meal increased the mean AUC of dasatinib following a single dose of 100 mg by 14%. The total calorie content of the high-fat meal was 985 kcal. The calories derived from fat, carbohydrates, and protein were 52%, 34%, and 14% for the high-fat meal.
The apparent volume of distribution is 2505 L (CV% 93%).
Binding of dasatinib to human plasma proteins in vitro was approximately 96% and of its active metabolite was 93%, with no concentration dependence over the range of 100 ng/mL to 500 ng/mL.
Dasatinib is a P-gp substrate in vitro.
The mean terminal half-life of dasatinib is 3 hours to 5 hours. The mean apparent oral clearance is 363.8 L/hr (CV% 81.3%).
Dasatinib is metabolized in humans, primarily by CYP3A4. CYP3A4 is the primary enzyme responsible for the formation of the active metabolite. Flavin-containing monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites.
The exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 5% of the AUC of dasatinib. The active metabolite of dasatinib is unlikely to play a major role in the observed pharmacology of the drug. Dasatinib also has several other inactive oxidative metabolites.
Elimination is primarily via the feces. Following a single radiolabeled dose of oral dasatinib, 4% of the administered radioactivity was recovered in the urine and 85% in the feces within 10 days. Unchanged dasatinib accounted for 0.1% of the administered dose in the urine and 19% of the administered dose in the feces with the remainder of the dose being metabolites.
Age (15 to 86 years old), sex, and renal impairment (creatinine clearance 21.6 mL/min to 342.3 mL/min as estimated by Cockcroft Gault) have no clinically relevant effect on the pharmacokinetics of dasatinib.
The pharmacokinetics of dasatinib were evaluated in 43 pediatric patients with leukemia or solid tumors at oral doses ranging from 60 mg/m² to 120 mg/m² once daily, taken with or without food. The pharmacokinetics showed dose proportionality with a dose-related increase in exposure. The mean Tmax was observed between 0.5 hours and 6 hours and the mean half-life was 2 hours to 5 hours. The geometric mean (CV%) of body weight normalized clearance in these 43 pediatric patients is 5.98 (41.5%) L/h/kg. In pediatric patients with a dosing regimen of 60 mg/m², the model simulated geometric mean (CV%) steady-state plasma average concentrations of dasatinib were 14.7 (64.6%) ng/mL (for 2 to <6 years old), 16.3 (97.5%) ng/mL (for 6 to <12 years old), and 18.2 (67.7%) ng/mL (for 12 years and older) [see DOSAGE AND ADMINISTRATION]. Dasatinib clearance and volume of distribution change with body weight in pediatric patients. Dasatinib has not been studied in patients < 1 year old.
Compared to subjects with normal liver function, patients with moderate hepatic impairment (Child Pugh B) had decreases in mean Cmax by 47% and mean AUC by 8%. Patients with severe hepatic impairment (Child Pugh C) had decreases in mean Cmax by 43% and in mean AUC by 28% compared to the subjects with normal liver function.
The coadministration of ketoconazole (strong CYP3A4 inhibitor) twice daily increased the mean Cmax of dasatinib by 4-fold and the mean AUC of dasatinib by 5-fold following a single oral dose of 20 mg.
The coadministration of rifampin (strong CYP3A4 inducer) once daily decreased the mean Cmax of dasatinib by 81% and the mean AUC of dasatinib by 82%.
Dasatinib is a time-dependent inhibitor of CYP3A4. Dasatinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1. Dasatinib does not induce CYP enzymes.
The administration of 30 mL of aluminum hydroxide/magnesium hydroxide 2 hours prior to a single dose of SPRYCEL was associated with no relevant change in the mean AUC of dasatinib; however, the mean Cmax of dasatinib was increased by 26%.
The simultaneous administration of 30 mL of aluminum hydroxide/magnesium hydroxide with a single dose of SPRYCEL was associated with a 55% reduction in the mean AUC of dasatinib and a 58% reduction in the mean Cmax of dasatinib.
The administration of a single dose of SPRYCEL 10 hours following famotidine (H2 antagonist) reduced the mean AUC of dasatinib by 61% and the mean Cmax of dasatinib by 63%.
The administration of a single 100 mg dose of SPRYCEL 22 hours following a 40 mg dose of omeprazole (proton pump inhibitor) at steady state reduced the mean AUC of dasatinib by 43% and the mean Cmax of dasatinib by 42%.
Dasatinib is a not an inhibitor of P-gp in vitro.
DASISION (Dasatinib vs Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients) (NCT00481247) was an open-label, multicenter, international, randomized trial conducted in adult patients with newly diagnosed chronic phase CML. A total of 519 patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily. Patients with a history of cardiac disease were included in this trial except those who had a myocardial infarction within 6 months, congestive heart failure within 3 months, significant arrhythmias, or QTc prolongation. The primary endpoint was the rate of confirmed complete cytogenetic response (CCyR) within 12 months. Confirmed CCyR was defined as a CCyR noted on two consecutive occasions (at least 28 days apart).
Median age was 46 years in the SPRYCEL group and 49 years in the imatinib groups, with 10% and 11% of patients ≥65 years of age, respectively. There were slightly more male than female patients in both groups (59% vs 41%). Fifty-three percent of all patients were Caucasian and 39% were Asian. At baseline, the distribution of Hasford scores was similar in the SPRYCEL and imatinib treatment groups (low risk: 33% and 34%; intermediate risk: 48% and 47%; high risk: 19% and 19%, respectively). With a minimum of 12 months follow-up, 85% of patients randomized to SPRYCEL and 81% of patients randomized to imatinib were still on study.
With a minimum of 24 months follow-up, 77% of patients randomized to SPRYCEL and 75% of patients randomized to imatinib were still on study and with a minimum of 60 months follow-up, 61% and 62% of patients, respectively, were still on treatment at the time of study closure.
Efficacy results are summarized in Table 13.
Table 13: Efficacy Results in a Randomized Newly Diagnosed
Chronic Phase CML Trial
| SPRYCEL (n=259) |
Imatinib (n=260) |
|
| Confirmed CCyRa | ||
| Within 12 months (95% CI) | 76.8% (71.2-81.8) | 66.2% (60.1-71.9) |
| P-value | 0.007* | |
| Major Molecular Responseb | ||
| 12 months (95% CI) | 52.1% (45.9-58.3) | 33.8% (28.1-39.9) |
| P-value | <0.0001 | |
| 60 months (95% CI) | 76.4% (70.8-81.5) | 64.2% (58.1-70.1) |
| a Confirmed CCyR is defined as a CCyR noted on
two consecutive occasions at least 28 days apart. b Major molecular response (at any time) was defined as BCR-ABL ratios ≤0.1% by RQ-PCR in peripheral blood samples standardized on the International scale. These are cumulative rates representing minimum follow up for the time frame specified. * Adjusted for Hasford score and indicated statistical significance at a pre-defined nominal level of significance. CI = confidence interval. |
||
The confirmed CCyR within 24, 36, and 60 months for SPRYCEL versus imatinib arms were 80% versus 74%, 83% versus 77%, and 83% versus 79%, respectively. The MMR at 24 and 36 months for SPRYCEL versus imatinib arms were 65% versus 50% and 69% versus 56%, respectively.
After 60 months follow-up, median time to confirmed CCyR was 3.1 months in 215 SPRYCEL responders and 5.8 months in 204 imatinib responders. Median time to MMR after 60 months follow-up was 9.3 months in 198 SPRYCEL responders and 15.0 months in 167 imatinib responders.
At 60 months, 8 patients (3%) on the dasatinib arm progressed to either accelerated phase or blast crisis while 15 patients (6%) on the imatinib arm progressed to either accelerated phase or blast crisis.
The estimated 60-month survival rates for SPRYCEL- and imatinib-treated patients were 90.9% (CI: 86.6%–93.8%) and 89.6% (CI: 85.2%–92.8%), respectively. Based on data 5 years after the last patient was enrolled in the trial, 83% and 77% of patients were known to be alive in the dasatinib and imatinib treatment groups, respectively, 10% were known to have died in both treatment groups, and 7% and 13% had unknown survival status in the dasatinib and imatinib treatment groups, respectively.
At 60 months follow-up in the SPRYCEL arm, the rate of MMR at any time in each risk group determined by Hasford score was 90% (low risk), 71% (intermediate risk) and 67% (high risk). In the imatinib arm, the rate of MMR at any time in each risk group determined by Hasford score was 69% (low risk), 65% (intermediate risk), and 54% (high risk).
BCR-ABL sequencing was performed on blood samples from patients in the newly diagnosed trial who discontinued dasatinib or imatinib therapy. Among dasatinib-treated patients the mutations detected were T315I, F317I/L, and V299L.
Dasatinib does not appear to be active against the T315I mutation, based on in vitro data.
The efficacy and safety of SPRYCEL were investigated in adult patients with CML or Ph+ ALL whose disease was resistant to or who were intolerant to imatinib: 1158 patients had chronic phase CML, 858 patients had accelerated phase, myeloid blast phase, or lymphoid blast phase CML, and 130 patients had Ph+ ALL. In a clinical trial in chronic phase CML, resistance to imatinib was defined as failure to achieve a complete hematologic response (CHR; after 3 months), major cytogenetic response (MCyR; after 6 months), or complete cytogenetic response (CCyR; after 12 months); or loss of a previous molecular response (with concurrent ≥10% increase in Ph+ metaphases), cytogenetic response, or hematologic response. Imatinib intolerance was defined as inability to tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity.
Results described below are based on a minimum of 2 years follow-up after the start of SPRYCEL therapy in patients with a median time from initial diagnosis of approximately 5 years. Across all studies, 48% of patients were women, 81% were white, 15% were black or Asian, 25% were 65 years of age or older, and 5% were 75 years of age or older. Most patients had long disease histories with extensive prior treatment, including imatinib, cytotoxic chemotherapy, interferon, and stem cell transplant. Overall, 80% of patients had imatinib-resistant disease and 20% of patients were intolerant to imatinib. The maximum imatinib dose had been 400–600 mg/day in about 60% of the patients and >600 mg/day in 40% of the patients.
The primary efficacy endpoint in chronic phase CML was MCyR, defined as elimination (CCyR) or substantial diminution (by at least 65%, partial cytogenetic response) of Ph+ hematopoietic cells. The primary efficacy endpoint in accelerated phase, myeloid blast phase, lymphoid blast phase CML, and Ph+ ALL was major hematologic response (MaHR), defined as either a CHR or no evidence of leukemia (NEL).
Dose-Optimization Trial
A randomized, open-label trial (NCT00123474) was conducted in adult patients with chronic phase CML to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. Patients with significant cardiac diseases, including myocardial infarction within 6 months, congestive heart failure within 3 months, significant arrhythmias, or QTc prolongation were excluded from the trial. The primary efficacy endpoint was MCyR in patients with imatinib-resistant CML. A total of 670 patients, of whom 497 had imatinib-resistant disease, were randomized to the SPRYCEL 100 mg once-daily, 140 mg once-daily, 50 mg twice-daily, or 70 mg twice-daily group. Median duration of treatment was 22 months.
Efficacy was achieved across all SPRYCEL treatment groups with the once-daily schedule demonstrating comparable efficacy (non-inferiority) to the twice-daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% CI [-6.8%–10.6%]); however, the 100-mg once-daily regimen demonstrated improved safety and tolerability.
Efficacy results are presented in Tables 14 and 15 for adult patients with chronic phase CML who received the recommended starting dose of 100 mg once daily.
Table 14: Efficacy of SPRYCEL in Adult Patients with
Imatinib-Resistant or -Intolerant Chronic Phase CML (minimum of 24 months
follow-up)
| All Patients | 100 mg Once Daily (n=167) |
| Hematologic Response Rate % (95% CI) | |
| CHRa | 92% (86-95) |
| Cytogenetic Response Rate % (95% CI) | |
| MCyRb | 63% (56-71) |
| CCyR | 50% (42-58) |
| a CHR (response confirmed after 4 weeks): WBC
≤ institutional ULN, platelets <450,000/mm³, no blasts or
promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in
peripheral blood, basophils in peripheral blood <20%, and no extramedullary
involvement. b MCyR combines both complete (0% Ph+ metaphases) and partial (>0%–35%) responses. |
|
Table 15: Long-Term MMR of SPRYCEL in the Dose
Optimization Trial: Adult Patients with Imatinib-Resistant or -Intolerant
Chronic Phase CMLa
| Minimum Follow-up Period | |||
| 2 Years | 5 Years | 7 Years | |
| Major Molecular Responseb % (n/N) | |||
| All Patients Randomized | 34% (57/167) | 43% (71/167) | 44% (73/167) |
| Imatinib-Resistant Patients | 33% (41/124) | 40% (50/124) | 41% (51/124) |
| Imatinib-Intolerant Patients | 37% (16/43) | 49% (21/43) | 51% (22/43) |
| a Results reported in recommended starting
dose of 100 mg once daily. b Major molecular response criteria: Defined as BCR-ABL/control transcripts ≤0.1% by RQ-PCR in peripheral blood samples. |
|||
Based on data 7 years after the last patient was enrolled in the trial, 44% were known to be alive, 31% were known to have died, and 25% had an unknown survival status.
By 7 years, transformation to either accelerated or blast phase occurred in nine patients on treatment in the 100 mg once-daily treatment group.
Dose-Optimization Trial
One randomized open-label trial (NCT00123487) was conducted in patients with advanced phase CML (accelerated phase CML, myeloid blast phase CML, or lymphoid blast phase CML) to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. The primary efficacy endpoint was MaHR. A total of 611 patients were randomized to either the SPRYCEL 140 mg once-daily or 70 mg twice-daily group. Median duration of treatment was approximately 6 months for both treatment groups. The once-daily schedule demonstrated comparable efficacy (non-inferiority) to the twice-daily schedule on the primary efficacy endpoint; however, the 140-mg once-daily regimen demonstrated improved safety and tolerability.
Response rates for patients in the 140 mg once-daily group are presented in Table 16.
Table 16: Efficacy of SPRYCEL in Imatinib-Resistant or
-Intolerant Advanced Phase CML and Ph+ ALL (2-Year Results)
| 140 mg Once Daily | ||||
| Accelerated (n=158) |
Myeloid Blast (n=75) |
Lymphoid Blast (n=33) |
Ph+ ALL (n=40) |
|
| MaHRa | 66% | 28% | 42% | 38% |
| (95% CI) | (59-74) | (18-40) | (26-61) | (23-54) |
| CHRa | 47% | 17% | 21% | 33% |
| (95% CI) | (40-56) | (10-28) | (9-39) | (19-49) |
| NELa | 19% | 11% | 21% | 5% |
| (95% CI) | (13-26) | (5-20) | (9-39) | (1-17) |
| MCyRb | 39% | 28% | 52% | 70% |
| (95% CI) | (31-47) | (18-40) | (34-69) | (54-83) |
| CCyR | 32% | 17% | 39% | 50% |
| (95% CI) | (25-40) | (10-28) | (23-58) | (34-66) |
| a Hematologic response criteria (all responses
confirmed after 4 weeks): Major hematologic response: (MaHR) = complete
hematologic response (CHR) + no evidence of leukemia (NEL). CHR: WBC ≤
institutional ULN, ANC ≥1000/mm³, platelets ≥100,000/mm³, no blasts
or promyelocytes in peripheral blood, bone marrow blasts ≤5%, <5%
myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral
blood <20%, and no extramedullary involvement. NEL: same criteria as for CHR
but ANC ≥500/mm³ and <1000/mm³, or platelets ≥20,000/mm³ and
≤100,000/mm³. b MCyR combines both complete (0% Ph+ metaphases) and partial (>0%–35%) responses. CI = confidence interval ULN = upper limit of normal range. |
||||
In the SPRYCEL 140 mg once-daily group, the median time to MaHR was 1.9 months (min-max: 0.7-14.5) for patients with accelerated phase CML, 1.9 months (min-max: 0.9-6.2) for patients with myeloid blast phase CML, and 1.8 months (min-max: 0.9-2.8) for patients with lymphoid blast phase CML.
In patients with myeloid blast phase CML, the median duration of MaHR was 8.1 months (min-max: 2.7-21.1) and 9.0 (min-max: 1.8-23.1) months for the 140 mg once-daily group and the 70 mg twice-daily group, respectively. In patients with lymphoid blast phase CML, the median duration of MaHR was 4.7 months (min-max: 3.0-9.0) and 7.9 months (min-max: 1.6-22.1) for the 140 mg once-daily group and the 70 mg twice-daily group, respectively. In patients with Ph+ ALL who were treated with SPRYCEL 140 mg once-daily, the median duration of MaHR was 4.6 months (min-max: 1.4-10.2). The medians of progression-free survival for patients with Ph+ ALL treated with SPRYCEL 140 mg once-daily and 70 mg twice-daily were 4.0 months (min-max: 0.4-11.1) and 3.1 months (min-max: 0.3-20.8), respectively.
The efficacy of SPRYCEL in pediatric patients was evaluated in two pediatric studies of 97 patients with chronic phase CML. Among 97 patients with chronic phase CML treated in two pediatric studies, an open-label, non-randomized dose-ranging trial (NCT00306202) and an open-label, non-randomized, single-arm trial (NCT00777036), 51 patients (exclusively from the single-arm trial) had newly diagnosed with chronic phase CML and 46 patients (17 from the dose-ranging trial and 29 from the single-arm trial) were resistant or intolerant to previous treatment with imatinib. Ninety-one of the 97 pediatric patients were treated with SPRYCEL tablets 60 mg/m² once daily (maximum dose of 100 mg once daily for patients with high BSA). Patients were treated until disease progression or unacceptable toxicity.
Baseline demographic characteristics of the 46 imatinib resistant or intolerant patients were: median age 13.5 years (range 2 to 20 years), 78.3% White, 15.2% Asian, 4.4% Black, 2.2% other, and 52% female. Baseline characteristics of the 51 newly diagnosed patients were: median age 12.8 years (range 1.9 to 17.8 years), 60.8% White, 31.4% Asian, 5.9% Black, 2% Other, and 49% female.
Median duration of follow-up was 5.2 years (range 0.5 to 9.3 years) for the imatinib resistant or intolerant patients and 4.5 years (range 1.3 to 6.4 years) for the newly diagnosed patients, respectively. Efficacy results for the two pediatric studies are summarized in Table 17.
Table 17 shows increasing trend for response for CCyR, MCyR, and MMR across time (3 months to 24 months). The increasing trend in response for all three endpoints is seen in both the newly diagnosed and imatinib resistant or intolerant patients.
Table 17: Efficacy of SPRYCEL in Pediatric Patients
with CP-CML Cumulative Response Over Time by Minimum Follow-Up Period
| 3 months | 6 months | 12 months | 24 months | |
| CCyR (95% CI) | ||||
| Newly diagnosed | 43.1% | 66.7% | 96.1% | 96.1% |
| (N = 51)a | (29.3, 57.8) | (52.1, 79.2) | (86.5, 99.5) | (86.5, 99.5) |
| Prior imatinib (N = 46)b | 45.7% (30.9, 61.0) | 71.7% (56.5, 84.0) | 78.3% (63.6, 89.1) | 82.6% (68.6, 92.2) |
| MCyR | ||||
| (95% CI) Newly diagnosed (N = 51)a | 60.8% (46.1, 74.2) | 90.2% (78.6, 96.7) | 98.0% (89.6, 100) | 98.0% (89.6, 100) |
| Prior imatinib (N = 46)b | 60.9% (45.4, 74.9) | 82.6% (68.6, 92.2) | 89.1% (76.4, 96.4) | 89.1% (76.4, 96.4) |
| MMR (95% CI) | ||||
| Newly diagnosed (N = 51)a | 7.8% (2.2, 18.9) | 31.4% (19.1, 45.9) | 56.9% (42.2, 70.7) | 74.5% (60.4, 85.7) |
| Prior imatinib (N = 46)b | 15.2% (6.3, 28.9) | 26.1% (14.3, 41.1) | 39.1% (25.1, 54.6) | 52.2% (36.9, 67.1) |
| aPatients from pediatric study of newly diagnosed
CP-CML receiving oral tablet formulation bPatients from pediatric studies of imatinib-resistant or -intolerant CP-CML receiving oral tablet formulation |
||||
With a median follow-up of 4.5 years in newly diagnosed patients, the median durations of CCyR, MCyR, MMR could not be estimated as more than half of the responding patients had not progressed at the time of data cut-off. Range of duration of response was (2.5+ to 66.5+ months for CCyR), (1.4 to 66.5+ months for MCyR), and (5.4+ to 72.5+ months for subjects who achieved MMR by month 24 and 0.03+ to 72.5+ months for subjects who achieved MMR at any time), where '+' indicates a censored observation.
With a median follow-up of 5.2 years in imatinib-resistant or - intolerant patients, the median durations of CCyR, MCyR, and MMR could not be estimated as more than half the responding patients had not progressed at the time of data cut-off. Range of duration of response was (2.4 to 86.9+ months for CCyR), (2.4 to 86.9+ months for MCyR), and (2.6+ to 73.6+ months for MMR), where '+' indicates a censored observation.
The median time to response for MCyR was 2.9 months (95% CI: 2.8 months, 3.5 months) in the pooled imatinib-resistant/intolerant CP-CML patients. The median time to response for CCyR was 3.3 months (95% CI: 2.8 months, 4.7 months) in the pooled imatinib-resistant/intolerant CP-CML patients. The median time to response for MMR was 8.3 months (95% CI: 5.0 months, 11.8 months) in the pooled imatinib- resistant/intolerant CP-CML patients.
The median time to response for MCyR was 3.0 months (95% CI: 2.8 months, 4.3 months) in the newly diagnosed treatment naive CP-CML patients. The median time to response for CCyR was 5.5 months (95% CI: 3.0 months, 5.7 months) in the newly diagnosed treatment-naive CP-CML patients. The median time to response for MMR was 8.9 months (95% CI: 6.2 months, 11.7 months) in the newly diagnosed treatment-naive CP-CML patients.
In the Phase II pediatric study, 1 newly diagnosed patient and 2 imatinib-resistant or -intolerant patients progressed to blast phase CML.
SPRYCEL®
(Spry-sell)
(dasatinib) tablets
What is SPRYCEL?
SPRYCEL® is a prescription medicine used to treat:
Before taking SPRYCEL, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, antacids, and herbal supplements. If you take an antacid medicine, take it 2 hours before or 2 hours after your dose of SPRYCEL.
How should I take SPRYCEL?
What are the possible side effects of SPRYCEL?
SPRYCEL may cause serious side effects, including:
Slowing of growth and development in children. Effects on bone growth and development in children with chronic phase CML have happened with SPRYCEL and can sometimes be severe.
The most common side effects of SPRYCEL in adults include:
The most common side effects of SPRYCEL in children include:
SPRYCEL may cause fertility problems in males and females. Talk to your healthcare provider if this is a concern for you.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of SPRYCEL.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store SPRYCEL?
Keep SPRYCEL and all medicines out of the reach of children.
General information about the safe and effective use of SPRYCEL.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SPRYCEL for a condition for which it is not prescribed. Do not give SPRYCEL to other people even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about SPRYCEL that is written for health professionals.
What are the ingredients in SPRYCEL?
Active ingredient: dasatinib
Inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium dioxide, and polyethylene glycol.
This Patient Information has been approved by the U.S. Food and Drug Administration.
